Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gradalis Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, SCHLOOP, ALLISON ELIZABETH. SCHLOOP, ALLISON ELIZABETH is the busiest examiner for the portfolio with 1 pending action. The prosecution is limited to 1 distinct art unit. This suggests a specific focus within the biotechnology and pharmaceuticals field for the current pending matter. With only 1 pending office action, the company's current USPTO engagement is very targeted.
The prosecution strategy for Gradalis Inc. is currently focused on 1 examiner and 1 distinct art unit. This concentration simplifies the management of the pending action and allows for a direct response to SCHLOOP, ALLISON ELIZABETH's findings. Practitioners can focus their efforts on the specific requirements of the examiner and the standards of the art unit involved. This concentration allows for a very specific focus on the issues raised in the office action, and practitioners can monitor the examiner's specific style for this case. The outcome of this interaction with SCHLOOP, ALLISON ELIZABETH will be the primary driver of the portfolio's immediate progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19240318 | NEOANTIGEN IMMUNOTHERAPY | SCHLOOP, ALLISON ELIZABETH | 34d |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19240318 | NEOANTIGEN IMMUNOTHERAPY | SCHLOOP, ALLISON ELIZABETH | 1683 | §103Other | Final Rejection | 34d | Pending | Jun 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial